ABVD is still the most commonly used standard regimen for patients at all stages, with better efficacy and reduced incidence of long-term side effects (especially 2nd tumor and fertility issues) compared to MOPP. Standard BEACOPP: Bleomycin 10 mg/m2 d8+VP-10 100 mg/m2 D1-3+ADM 25 mg/m2 d1+CTX 600 mg/m2 D 1+VCR 1.4 mg/m2 D8+methylbenzylhydrazine 100 mg/m2 po D1-7+prednisone 40 mg/m2 D1-14. Intensification BEACOPP: Bleomycin 10 mg/m2 d8+VP-10 200 mg/m2 D1-3+ADM 35 mg/m2 d1+CTX 1200 mg/m2 D 1+VCR 1.4 mg/m2 D8+methylbenzylhydrazine 100 mg/m2 po D1-7+prednisone 40 mg/m2 D1-14. For poor prognosis HL-enhanced BEACOPP improves efficacy but has high hematologic toxicity, high cumulative incidence of 10-year acute myeloid leukemia/myelodysplasia (AML/MDS), and a high risk of infertility. Standford V : The cumulative doses of doxorubicin and bleomycin are very low compared to ABVD x 6 (150 mg/m2 vs. 300 mg/m2, 30 units/m2 vs. 120 units/m2) and therefore protect against conception and have low pulmonary and cardiotoxicity. However, randomized clinical trials have shown that Stanford V has a lower CR rate and no better or worse PFS and OS than ABVD. Radiotherapy is needed for patients with large mediastinum (with recurrence rates up to 40-50% without radiotherapy) and for patients who do not achieve CR after chemotherapy, but for excluded cases it is not worthwhile due to increased complication rates and no benefit for 10-year OS is not beneficial and therefore the value remains controversial.